Aneta Nowicka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aneta Nowicka has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Lidia Gil
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland
2 shared publications - Agnieszka Karbownik
Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806 Poznań, Poland
1 shared publication - Anna Sowińska
Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland
1 shared publication - Barbara Więckowska
Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland
1 shared publication - Edyta Szałek
Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806 Poznań, Poland
1 shared publication - Hanna Tomczak
Faculty of Medicine and Health Sciences, University of Kalisz
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Annals of Hematology
Evolving infectious epidemiology in acute myeloid leukemia in the contemporary era: a 13-year retrospective, single-center analysis of induction therapies
We evaluated the 13-year (2012–2025) evolution of infectious epidemiology in a Polish acute myeloid leukemia (AML) induction cohort, contextualizing these findings within shifting antimicrobial resistance (AMR), the SARS-CoV-2 pandemic, changing prophylaxis protocols (including fluoroquinolone cessation), and evolving diagnostic methodologies. Secondarily, we compared historical standard induction therapy (SIT) and novel targeted induction (NIT) regimens. This exploratory, retrospective, single-center study assessed induction-related infections in 219 newly diagnosed AML adults. We observationally evaluated temporal shifts in etiology and AMR, utilizing an interrupted time series approach to assess the 2018 cessation of universal fluoroquinolone prophylaxis, alongside a secondary comparison of SIT (n=189) and NIT (n=30) cohorts. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.Overall 30-day mortality was 8.2%. Comparing the pre-2018 (active fluoroquinolone) and post-2018 (discontinued) eras, proportional bloodstream infections (BSI; 40.6% vs. 34.7%) and multidrug-resistant organism (MDRO) rates (77.2% vs. 68.6%) decreased, without a compensatory Gram-negative surge. Concurrently, 30-day mortality dropped from 11.9% to 5.1%. Between NIT and SIT, incidences of microbiologically documented infections (53.3% vs. 51.3%), invasive fungal diseases (6.7% vs. 13.2%), and BSI (33.3% vs. 38.1%) were comparable. The higher incidence of VIM-producing Pseudomonas aeruginosa (30.8% vs. 3.3%; p=0.005) and SARS-CoV-2 (53.3% vs. 33.3%; p=0.034) in NIT was confounded by total overlap with the pandemic era and advanced molecular diagnostics. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.
- 15 October 2026
- Published by Springer Nature in Annals of Hematology
Open AccessEvolving infectious epidemiology in acute myeloid leukemia in the contemporary era: a 13-year retrospective, single-center analysis of induction therapies
We evaluated the 13-year (2012–2025) evolution of infectious epidemiology in a Polish acute myeloid leukemia (AML) induction cohort, contextualizing these findings within shifting antimicrobial resistance (AMR), the SARS-CoV-2 pandemic, changing prophylaxis protocols (including fluoroquinolone cessation), and evolving diagnostic methodologies. Secondarily, we compared historical standard induction therapy (SIT) and novel targeted induction (NIT) regimens. This exploratory, retrospective, single-center study assessed induction-related infections in 219 newly diagnosed AML adults. We observationally evaluated temporal shifts in etiology and AMR, utilizing an interrupted time series approach to assess the 2018 cessation of universal fluoroquinolone prophylaxis, alongside a secondary comparison of SIT (n=189) and NIT (n=30) cohorts. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.Overall 30-day mortality was 8.2%. Comparing the pre-2018 (active fluoroquinolone) and post-2018 (discontinued) eras, proportional bloodstream infections (BSI; 40.6% vs. 34.7%) and multidrug-resistant organism (MDRO) rates (77.2% vs. 68.6%) decreased, without a compensatory Gram-negative surge. Concurrently, 30-day mortality dropped from 11.9% to 5.1%. Between NIT and SIT, incidences of microbiologically documented infections (53.3% vs. 51.3%), invasive fungal diseases (6.7% vs. 13.2%), and BSI (33.3% vs. 38.1%) were comparable. The higher incidence of VIM-producing Pseudomonas aeruginosa (30.8% vs. 3.3%; p=0.005) and SARS-CoV-2 (53.3% vs. 33.3%; p=0.034) in NIT was confounded by total overlap with the pandemic era and advanced molecular diagnostics. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.
- Top Cited PapersOpen Access
- 31 January 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 165, 108447
Fecal microbiota transplantation for carbapenem-resistant Pseudomonas spp. colonization in hematology patients: long-term real-world data
- 31 January 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 165, 108447
Top Cited PapersOpen AccessFecal microbiota transplantation for carbapenem-resistant Pseudomonas spp. colonization in hematology patients: long-term real-world data
- Open Access
- 18 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1761
Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML—One Step Closer to Personalized Medicine
Increasing evidence demonstrates the mutualistic connection between the microbiome and acute myeloid leukemia (AML) treatment. Drugs disrupt the microbial balance and, conversely, changes in the microbiome influence therapy. A new field, pharmacomicrobiomics, examines the role of the microbiome in pharmacokinetics, pharmacodynamics, and drug toxicity. The multimodal therapeutic management of AML, along with disease-related immunosuppression, infection, and malnutrition, creates the unique microbial profile of AML patients, in which every delicate modification plays a crucial role in pharmacotherapy. While both preclinical and real-world data have confirmed a bilateral connection between standard chemotherapy and the microbiome, the impact of novel targeted therapies and immunotherapy remains unknown. Multi-omics technologies have provided qualitative and mechanistic insights into specific compositional and functional microbial signatures associated with the outcomes of AML therapy, but require a large-scale investigation to draw reliable conclusions. In this review, we outline the role of the microbiome within the therapeutic landscape of AML, focusing on the determinants of post-treatment dysbiosis and its effects on the therapeutic response and toxicity. We explore emerging strategies for microbiota modulation, highlighting their safety and efficacy. Advances in microbiome-based approaches are an inevitable step toward precision medicine in AML. However, clinical research in a well-defined group of immunocompromised patients is needed to study their variable effects on human health and determine safety issues.
- 18 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1761
Open AccessMicrobial Crosstalk with Therapy: Pharmacomicrobiomics in AML—One Step Closer to Personalized Medicine
Increasing evidence demonstrates the mutualistic connection between the microbiome and acute myeloid leukemia (AML) treatment. Drugs disrupt the microbial balance and, conversely, changes in the microbiome influence therapy. A new field, pharmacomicrobiomics, examines the role of the microbiome in pharmacokinetics, pharmacodynamics, and drug toxicity. The multimodal therapeutic management of AML, along with disease-related immunosuppression, infection, and malnutrition, creates the unique microbial profile of AML patients, in which every delicate modification plays a crucial role in pharmacotherapy. While both preclinical and real-world data have confirmed a bilateral connection between standard chemotherapy and the microbiome, the impact of novel targeted therapies and immunotherapy remains unknown. Multi-omics technologies have provided qualitative and mechanistic insights into specific compositional and functional microbial signatures associated with the outcomes of AML therapy, but require a large-scale investigation to draw reliable conclusions. In this review, we outline the role of the microbiome within the therapeutic landscape of AML, focusing on the determinants of post-treatment dysbiosis and its effects on the therapeutic response and toxicity. We explore emerging strategies for microbiota modulation, highlighting their safety and efficacy. Advances in microbiome-based approaches are an inevitable step toward precision medicine in AML. However, clinical research in a well-defined group of immunocompromised patients is needed to study their variable effects on human health and determine safety issues.
- Open Access
- 21 October 2024
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (9)
Microbial metabolomics in acute myeloid leukemia: From pathogenesis to treatment
Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.
- 21 October 2024
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (9)
Open AccessMicrobial metabolomics in acute myeloid leukemia: From pathogenesis to treatment
Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.